Wülfrath, Germany

Jens-Kerim Ergüden


Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jens-Kerim Ergüden: Innovator in CNS Disease Treatment

Introduction

Jens-Kerim Ergüden is a notable inventor based in Wülfrath, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the treatment of central nervous system (CNS) diseases. His innovative work has the potential to impact the lives of many individuals suffering from cognitive disorders.

Latest Patents

Ergüden holds a patent for "3-oxo-2,1-benzisoxazol-1(3H)-carboxamides for treatment of CNS diseases." This invention relates to novel compounds that can be used in the production of medicaments aimed at treating various CNS disorders, including Alzheimer's disease and other forms of dementia. The patent outlines the chemical structure and potential applications of these compounds, emphasizing their therapeutic benefits.

Career Highlights

Jens-Kerim Ergüden is associated with Bayer Aktiengesellschaft, a leading global pharmaceutical and life sciences company. His work at Bayer has allowed him to focus on developing innovative solutions for complex health issues. With a patent portfolio that includes 1 patent, Ergüden has established himself as a key player in the field of CNS research.

Collaborations

Throughout his career, Ergüden has collaborated with esteemed colleagues, including Toshiya Moriwaki and Chantal Fürstner. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the quality of research and development in the pharmaceutical industry.

Conclusion

Jens-Kerim Ergüden's contributions to the treatment of CNS diseases through his innovative patents highlight the importance of research and development in the pharmaceutical field. His work not only advances scientific knowledge but also holds promise for improving patient outcomes in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…